Anti-Japanese Encephalitis Virus (Clone: JEV-69)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 100 µg |
| Isotype : | Human IgG1 |
| Purification : | ≥95% monomer by analytical SEC |
| Content : | ≥ 5.0 mg/ml Formulation : This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added |
| Storage condition : | Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles. |
| Alternative Name : | JEV |
| Immunogen Information : | A panel of human mAbs against JEV, including JEV-69, was generated from donors immunized with a GIII vaccine strain (JEV-SA14-14-2). |
Reactivity Species : Japanese Encephalitis-Virus
Expression Host : HEK-293
Endotoxin Level : ≤ 1.0 EU/mg as determined by the LAL method
Specificity : Clone JEV-69 activity is directed against DIII-LR of the E protein. JEV-69 has no cross-reactivity to West Nile Virus or Zika Virus E proteins.
Background : Japanese Encephalitis Virus (JEV) is a mosquito-borne, enveloped positive-stranded RNA virus in the Flavivirus genus endemic to Asia and parts of the western Pacific1. Symptomatic JEV infection is most common in children in areas of endemicity or travelers to those regions. Severe symptoms occur in ~1% of cases, with a case-fatality ratio of 20–30%. Survivors often have neurologic, cognitive, or psychiatric sequelae issues. Five JEV genotypes have been identified, and existing vaccines are derived from historically predominant GIII strains2.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
